Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Noncoding RNA TY1 reverses fibrosis in systemic sclerosis by attenuating the cGAS/STING pathway
Xaviar M. Jones, Salwa Soussi, Alessandra Ciullo, Kara Tsi, Weixin Liu, Liang Li, Mario Fournier, Thassio Mesquita, Alberto M. Marchevsky, Nunzio Bottini, Francesco Boin, Ahmed G.E. Ibrahim, Eduardo Marbán
Xaviar M. Jones, Salwa Soussi, Alessandra Ciullo, Kara Tsi, Weixin Liu, Liang Li, Mario Fournier, Thassio Mesquita, Alberto M. Marchevsky, Nunzio Bottini, Francesco Boin, Ahmed G.E. Ibrahim, Eduardo Marbán
View: Text | PDF
Research Article Cardiology Inflammation

Noncoding RNA TY1 reverses fibrosis in systemic sclerosis by attenuating the cGAS/STING pathway

  • Text
  • PDF
Abstract

DNA damage and the cGAS/STING innate immunity pathway have been associated with fibrosis in systemic sclerosis (SSc), but a cause-and-effect role has not been established. Here we report the effects of TY1, a noncoding RNA drug of the exomer class that suppresses DNA damage and thereby inhibits cGAS/STING, in human SSc cells and in 2 preclinical models of SSc. Macrophages from patients with SSc exhibited high levels of phosphorylated DNA damage, cGAS, 2’3’-cGAMP, STING, and IFNs, all of which decreased after exposure to TY1. In mice that had been injected s.c. with bleomycin to model SSc, exercise tolerance, cardiac function, lung hydroxyproline, and skin thickness reverted to normal levels after oral administration of TY1. Similar therapeutic benefits were evident in the genetic tsk-1 mouse model of SSc. TY1 attenuated fibrosis and/or fibrotic gene expression in both mouse models of SSc and in human SSc skin fibroblasts. Our findings support the hypothesis that cGAS/STING, activated by DNA damage, is a key driver of fibrosis in SSc.

Authors

Xaviar M. Jones, Salwa Soussi, Alessandra Ciullo, Kara Tsi, Weixin Liu, Liang Li, Mario Fournier, Thassio Mesquita, Alberto M. Marchevsky, Nunzio Bottini, Francesco Boin, Ahmed G.E. Ibrahim, Eduardo Marbán

×

Figure 4

Transcriptomic and protein-level attenuation of cGAS-STING and downstream effectors by TY1 in skin from bleomycin-injected mice.

Options: View larger image (or click on image) Download as PowerPoint
Transcriptomic and protein-level attenuation of cGAS-STING and downstrea...
(A) Heatmap of transcriptomic sequencing from lesional skin tissue from control and bleomycin-injected mice treated with vehicle or TY1 (n = 3–4 biological replicates/group). (B) Gene ontology analysis identifies downregulation of DNA damage response, IFN, and inflammatory pathways as major implicated in lesional skin in TY1-treated mice. (C) Downregulation of interferon-stimulated and inflammatory genes. (D) qPCR validation TY1 inflammatory modulation in skin tissue from control and bleomycin-injected mice treated with vehicle or TY1 (n = 3–4 biological replicates/group). (E) Trex1 expression in skin tissue from control and bleomycin-injected mice treated with vehicle, scramble, or TY1 by qPCR (n = 3–4 biological replicates/group). (F and G) Representative images and analysis of Western blots showing decreases of cGAS, STING, TBK-1, and IRF-3 protein levels in skin tissue of animals receiving TY1 compared with vehicle (n = 3 biological replicates/group). (H) Measurement of IFN-β in lesional skin from control and bleomycin-injected mice treated with vehicle or TY1 by ELISA (n = 3 biological replicates/group). Statistical analysis by repeated-measures ANOVA followed by Tukey post hoc test with 95% CI; *P < 0.05, **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts